Neuralstem, Inc. (NYSE MKT:CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced that it has been approved for listing on the NASDAQ Capital Market under the symbol “CUR.” The Company’s common stock will continue to trade on the NYSE MKT until the market close on July 10, 2015. Trading on the NASDAQ Capital Market is expected to commence on July 13, 2015. (Original Source)
Shares of Neuralstem closed last Friday at $2.02 . CUR has a 1-year high of $4.40 and a 1-year low of $1.46. The stock’s 50-day moving average is $1.82 and its 200-day moving average is $2.51.
On the ratings front, Neuralstem has been the subject of a number of recent research reports. In a report issued on May 11, Brean Murray Carret analyst Jonathan Aschoff reiterated a Buy rating on CUR, with a price target of $8, which represents a potential upside of 296.0% from where the stock is currently trading. Separately, on March 18, Maxim Group’s Jason Kolbert reiterated a Sell rating on the stock and has a price target of $0.25.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Jonathan Aschoff and Jason Kolbert have a total average return of 11.1% and 1.5% respectively. Aschoff has a success rate of 53.8% and is ranked #232 out of 3681 analysts, while Kolbert has a success rate of 42.0% and is ranked #1566.
Neuralstem Inc is a biotechnology company. It is engaged in the development and commercialization of treatments for central nervous system disease based on transplanting human neural stem cells and the use of small molecule drugs.